In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Letian Xia *Department of Clinical Laboratory, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.ORCID 0009-0003-4572-5136 Mengjiao Shi *School of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.ORCID 0009-0004-8853-2868 Chenfei Li *Department of Medical Laboratory Technology, Feng Xian People's Hospital, Xuzhou, Jiangsu, People's Republic of China.ORCID 0009-0005-5955-2680 Yaqi ZhuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.ORCID 0009-0001-9788-1929 Fei JiangDepartment of Clinical Laboratory, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.ORCID 0000-0002-4462-0549 Shulong ZhaoDepartment of Clinical Laboratory, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.ORCID 0000-0001-6334-7296 Shuang SongDepartment of Clinical Laboratory, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.ORCID 0009-0004-9604-4493 Youzhen MaSchool of Life Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.ORCID 0000-0001-9986-2409 Lei ChengDepartment of Medical Laboratory Technology, Feng Xian People's Hospital, Xuzhou, Jiangsu, People's Republic of China.ORCID 0009-0005-5280-315X Haiquan KangDepartment of Clinical Laboratory, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.ORCID 0000-0002-0424-1317 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The emergence of carbapenem-resistant hypervirulent IMPORTANCE: The emergence of bacterial pathogens that combine hypervirulence with advanced antimicrobial resistance poses a significant challenge for modern healthcare. This study comprehensively analyzes a concerning clinical strain: ST11-KL64
Indexed as
Bacterial Proteinsbeta-LactamasesCarbapenem-Resistant EnterobacteriaceaeKlebsiella InfectionsKlebsiella pneumoniaeAnimalsAnti-Bacterial AgentsCarbapenemsCeftazidimeChinaDrug Resistance, Multiple, BacterialEvolution, MolecularFemaleHumansMaleMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial Proteinsbeta-lactamase KPC-2, Klebsiella pneumoniaebeta-lactamase NDM-1beta-LactamasesCarbapenemsCeftazidimeThird Generation Cephalosporinscarbapenem-resistant Klebsiella pneumoniaehypervirulenceKPC-2molecular epidemiologyNDM-1plasmid stability
Identifiers
PMID41660983
PMCPMC12955449
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390